An open-label, phase I study of BM-ca in indolent B cell Non-Hodgkin's lymphoma patients, refractory to or relapsed after Rituximab treatment.

Trial Profile

An open-label, phase I study of BM-ca in indolent B cell Non-Hodgkin's lymphoma patients, refractory to or relapsed after Rituximab treatment.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs BM ca (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jul 2012 Actual end date (6 Jul 2012) added as reported by University Hospital Medical Information Network - Japan.
    • 06 Jul 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 29 Mar 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top